ArticleDrug discovery today. Disease models2011
Article in Drug discovery today. Disease models, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Modeling metastasis - leveraging novel tools to streamline discovery in advanced cancer.Disease models & mechanisms · 2025Review
- Article
- Review
- How to Improve SBRT Outcomes in NSCLC: From Pre-Clinical Modeling to Successful Clinical Translation.Cancers · 2022Review
- Immuno-oncology trends: preclinical models, biomarkers, and clinical development.Journal for immunotherapy of cancer · 2022Review
- Mutational drivers of cancer cell migration and invasion.British journal of cancer · 2021Review
- Automated platform for cell selection and separation based on four-dimensional motility and matrix degradation.The Analyst · 2020Article
- β-Catenin mutations as determinants of hepatoblastoma phenotypes in mice.The Journal of biological chemistry · 2019Article
- Mouse models of metastasis: progress and prospects.Disease models & mechanisms · 2017Review
- Evaluation of Lung Metastasis in Mouse Mammary Tumor Models by Quantitative Real-time PCR.Journal of visualized experiments : JoVE · 2016Article
- Rebuilding cancer metastasis in the mouse.Molecular oncology · 2013Review
- CCL2 at the crossroad of cancer metastasis.JAK-STAT · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor invasion and metastasis is a multi-step process that requires adaptation of cancer cells to conditions that they encounter during their journey to distant body sites. Understanding the molecular processes that underlie this adaptation is of exceeding importance because most cancer patients die because of metastases rather than primary tumors. In this review we assess genetically engineered mouse models (GEMMs) that have been established to investigate mechanisms of cancer invasion and metastasis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.